TissueGene Company Profile
Starting in 1997, the founders of TissueGene sought to uncover different surgical and gene-based therapeutics for a variety of arthritic conditions. The diligence soon paid off in the form of the first successful animal model for cartilage repair. Subsequently, in the middle of 1999, TissueGene, Inc was incorporated in the United States. TissueGene's initial findings resulted in the focused development of a proprietary cell mediated genetic technology capable of treating and regenerating damaged tendons, ligaments, cartilage and bones. The company began using a form of cell mediated gene therapy to deliver a regenerative protein to damaged tissue, which catalyzes rapid and permanent repair of the injured site without the need for surgery
Location
209 Perry Parkway, Suite 13
Gaithersburg
Maryland
20877
United States of America
Contact
Phone: (301) 921-6000
Fax: (301) 921-6011
Email: contact@tissuegene.com
News Articles
TissueGene Completes Enrollment in U.S. Phase II Study of TG-C in Patients with Knee Osteoarthritis
ROCKVILLE, Md., Nov. 14, 2012 /PRNewswire/ -- TissueGene, Inc. announced today that it has completed patient enrollment for a U.S. Phase II clinical trial of TG-C in patients suffering from severe ost...
TissueGene-C: Completed Phase II enrollment
TissueGene completes patient enrollment in US Phase II trial of TG-C therapy
TissueGene has completed enrolling patients in a US-based Phase II trial of its TG-C therapy, designed to treat patients with Grade 3 chronic degenerative joint disease (DJD) of the knee.
TissueGene completes enrollment in phase II TG-C study of in knee osteoarthritis
TissueGene, is a Rockville, Md.-based biopharmaceutical company focused on developing novel regenerative therapies, has completed patient enrollment for a U.S. phase II clinical trial of TG-C in patie...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee
The study is being conducted to investigate the safety and activity of TissueGene-C injected into the knee joint of patients with chronic degenerative joint disease (DJD) who will be under...
Companies
Starting in 1997, the founders of TissueGene sought to uncover different surgical and gene-based therapeutics for a variety of arthritic conditions. The diligence soon paid off in the form of the firs...
More Information about "TissueGene" on BioPortfolio
We have published hundreds of TissueGene news stories on BioPortfolio along with dozens of TissueGene Clinical Trials and PubMed Articles about TissueGene for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of TissueGene Companies in our database. You can also find out about relevant TissueGene Drugs and Medications on this site too.
